Related Experiment Video

Updated: Aug 10, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

An Update on the Treatment of Papillary Renal Cell Carcinoma

Neal S Chawla1, Nicolas Sayegh2, Sweta Prajapati1

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Cancers
|February 11, 2023
PubMed

Insights

Papillary renal cell carcinoma (pRCC), a common kidney cancer, shows slower treatment progress than other subtypes due to its diverse nature. This review covers pRCC biology and clinical trials, highlighting future research directions.

Area of Science:

  • Oncology
  • Nephrology
  • Cancer Biology

Background:

  • Papillary renal cell carcinoma (pRCC) is the second most frequent kidney cancer subtype, accounting for 15% of cases.
  • Therapeutic advancements in pRCC, including targeted therapies and immune checkpoint inhibitors, have lagged behind clear cell renal cell carcinoma (ccRCC).
  • The heterogeneity among pRCC subtypes contributes to challenges in treatment development.

Purpose of the Study:

  • To review the distinct biological characteristics of papillary renal cell carcinoma.
  • To discuss the most impactful clinical trials conducted to date for pRCC.
  • To provide an outlook on anticipated ongoing clinical trials in pRCC research.

Main Methods:

  • Literature review of distinct biological features of pRCC.
  • Analysis of key clinical trials in pRCC treatment.
  • Synthesis of current research trends and future trial directions.

Main Results:

  • pRCC exhibits significant biological heterogeneity, impacting therapeutic responses.
  • Several clinical trials have explored targeted therapies and immunotherapies with varying success.
  • Ongoing trials are focusing on histology and biology-driven approaches.

Conclusions:

  • Understanding pRCC's unique biology is crucial for developing effective treatments.
  • Clinical trial progress in pRCC necessitates tailored, subtype-specific strategies.
  • Future research holds promise for improved outcomes in papillary renal cell carcinoma.
Keywords:
papillaryrenal cell carcinoma

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
228
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
615